MARINUS PHARMACEUTICALS INC (NASDAQ:MRNS) Move as Institutional Investors’ Sentiment Crashes

May 27, 2018 - By Marguerite Chambers

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Logo

Sentiment for MARINUS PHARMACEUTICALS INC (NASDAQ:MRNS)

MARINUS PHARMACEUTICALS INC (NASDAQ:MRNS) institutional sentiment decreased to 2 in Q4 2017. Its down -0.80, from 2.8 in 2017Q3. The ratio fall, as 36 active investment managers increased or opened new positions, while 18 trimmed and sold stock positions in MARINUS PHARMACEUTICALS INC. The active investment managers in our partner’s database reported: 20.53 million shares, up from 18.97 million shares in 2017Q3. Also, the number of active investment managers holding MARINUS PHARMACEUTICALS INC in their top 10 positions decreased from 2 to 1 for a decrease of 1. Sold All: 7 Reduced: 11 Increased: 13 New Position: 23.

Marinus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. The company has market cap of $239.48 million. The firm is developing ganaxolone, a small molecule, which is in Phase III clinical trials to treat adults with refractory focal onset epileptic seizures; and is in Phase II clinical trials for the treatment of genetic orphan disorders, as well as is in Phase II clinical trial to treat Fragile X Syndrome, an orphan indication. It currently has negative earnings. The firm is also developing ganaxolone IV formulation to treat status epilepticus.

The stock decreased 1.83% or $0.11 during the last trading session, reaching $5.91. About 1.11 million shares traded or 17.28% up from the average. Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) has risen 130.72% since May 27, 2017 and is uptrending. It has outperformed by 119.17% the S&P500.

Granite Point Capital Management L.P. holds 1.82% of its portfolio in Marinus Pharmaceuticals, Inc. for 2.28 million shares. New Leaf Venture Partners L.L.C. owns 425,000 shares or 1.62% of their US portfolio. Moreover, Iguana Healthcare Management Llc has 0.53% invested in the company for 100,000 shares. The Massachusetts-based Cormorant Asset Management Llc has invested 0.43% in the stock. 683 Capital Management Llc, a New York-based fund reported 550,000 shares.

Since January 1, 0001, it had 0 insider buys, and 2 insider sales for $10.05 million activity.

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Ratings Coverage

Ratings analysis reveals 100% of Marinus’s analysts are positive. Out of 2 Wall Street analysts rating Marinus, 2 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $13.0 while the high is $1500. The stock’s average target of $14 is 136.89% above today’s ($5.91) share price. MRNS was included in 2 notes of analysts from March 19, 2018. Robert W. Baird initiated Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) rating on Wednesday, May 23. Robert W. Baird has “Buy” rating and $1500 target. On Monday, March 19 the stock rating was initiated by Mizuho with “Buy”.

More notable recent Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) news were published by: Fool.com which released: “Here’s Why Marinus Pharmaceuticals Rose as Much as 18.4% Today” on May 24, 2018, also Schaeffersresearch.com with their article: “One Defense Stock Boosted By Nixed North Korea Summit” published on May 24, 2018, Seekingalpha.com published: “Premarket analyst action – healthcare” on May 24, 2018. More interesting news about Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) were released by: Benzinga.com and their article: “Benzinga’s Daily Biotech Pulse: Eiger And Melinta Fall On Offerings, Apellis And Marinus Rise On Bullish Ratings” published on May 24, 2018 as well as Benzinga.com‘s news article titled: “25 Stocks Moving In Thursday’s Pre-Market Session” with publication date: May 24, 2018.

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: